Updates

Ref: ADL/SE/2026-27/46 September 26, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400051 BSE CODE: 524348 NSE SYMBOL: AARTIDRUGS Dear Sir/Madam, Sub: Presentation to Shareholders Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Please find attached herewith presentation made to the shareholders of the Company at the 41st Annual General Meeting held today i.e. September 26, 2026 for your records. Kindly take the same on record. Thanking you, Yours faithfully, FOR AARTI DRUGS LIMITED RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M.No.: F12932 Aarti Drugs Limited Annual General Meeting September 26, 2026 FY 2025-26 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Aarti Drugs Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. Company & Business Overview Journey 2024 Forayed into the personal care segment with the commissioning of a greenfield project for 2021 dermatology products at Tarapur Surpassed a consolidated turnover of 2026 Rs. 2,000 Crores Commissioned and ramped Pinnacle Life Science Private Limited up the Sayakha surpassed a turnover of Rs. 200 Crores methylamines facility, strengthening backward Surpassed a Profit After Tax (PAT) of integration for the Rs. 200 Crores Metformin portfolio 2022 This image cannot currently be displayed. Crossed Rs. 2,500 crores Received USFDA approval 2008 Consolidated Turnover for our oncology facility and One of our facilities got UK MHRA approval for our approved by the USFDA oral solid dosage (OSD) facility 1996 2014 Expanded our business through Received EU GMP the merger of several group Crossed Rs. 1,000 crores turnover certifications for the entities, creating a stronger and oncology and general Expanded into the formulations capsule lines more integrated organisation segment with our 100% subsidiary Pinnacle Life Science Private Limited 2003 Listed On National Stock Exchange of India Limited 1984 Incorporation 1993 Listed on BSE Limited Leadership in API Manufacturing Over a decade, API manufacturing has transitioned towards highly regulated, specialized business 14 6,876 1 Largest producer of Nimesulide in the world Manufacturing Facilities MT/Monthly Capacity 2 Largest producer of Ketoconazole in the world 80+ 50+ 3 Largest producer of Metronidazole Benzoate in the world Finished Products API Molecules 4 Largest producer of Tinidazole in the world 2,200+ ~38% 5 Largest producer in Fluoroquinolones group in the world Employees Export Revenue 6 One of the leading producers of Metformin in the world 1,59,500+ 100+ Sq.m. Plant Area Presence across countries 7 Largest producer of Metronidazole in India Diversified Presence across Segments Presence Across APIs, Formulation, Specialty Chemicals, Intermediates Segments Active Pharmaceuticals Ingredients (API) Formulations Specialty Chemicals, Intermediates & Others  Diversified into formulations in 2014 via wholly  Backward integrated to supply intermediates for  Leading API producer with 50+ molecules across owned subsidiary. antibiotics, antifungals, anti-inflammatories, and therapeutic categories including antibiotics,  Flexible manufacturing model: In-house + cardiovascular APIs. antiprotozoals, anti-inflammatories, anti-diabetics, outsourced production backed by strong R&D  Manufacturer of specialty chemicals in Benzene and and anti-fungals  UKMHRA / PICS approved Chloro-sulphonic chemistries  Global Leader:  WHO-GMP approved plant in Baddi, Himachal  Installed capacity: 34,308 MTPA • Largest manufacturer of 5 molecules globally Pradesh  API Infrastructure:  Oncology formulation is USFDA approved • 9 manufacturing units contributing ~92% of  Installed capacity: total revenues • 3 billion tablets • Installed capacity: 48,204 MTPA • 300 million capsules Manufacturing Footprint Baddi Pinnacle Plant Formulation Plant WHO-GMP  The capacity of Multi- purpose plant ranges from Sarigam-1 kilograms to multi tons levels WHO-GMP  Long term experience of Sarigam-2 Multi-step synthesis and WHO-GMP/ COFEPRIS/CEP fractionations at high temperatures Sayakha WHO-GMP  Total reaction capacity in excess of 1300 KL, consisting of SS and GL reactors across E-22 W-61 its units, varying from 0.5 KL  Australian Government – Department of EUGMP & WHO-GMP Health and Ageing - Therapeutic Goods – 18 KL Administration E-120  EUGMP / WHO-GMP / Japanese Accreditation WHO-GMP  USFDA* E-9/3 Capacities (MT) 2022-23 2023-24 2024-25 2025-26 G-60 E-21 ISO-9001:2008  ANVISA-Brazil  WHO-GMP Installed 51,126 57,179 61,053 82,512  WHO-GMP  K-FDA(Korean FDA) T-150  COFEPRIS-MEXICO Intermediate Production 38,215 41,116 44,915 53,139 ISO Certification N-198 K-40 G61/62 Captive 9,382 9,864 11,621 13,208 EUGMP, WHO-GMP WHO-GMP / ISO certification & ISO Certification COFEPRIS Net Production 28,834 31,251 33,294 39,931 Maps not to scale . All data , information , and maps are provided " as is " without warranty or any representation of accuracy Diversified Geographic Presence North America Europe 11 % 15 % 12 % 12 % FY25 FY26 FY25 FY26 Russia Egypt Asia Latin America China Türkiye 52 % 49 % 14 % 12 % Bangladesh FY25 FY26 FY25 FY26 Switzerland Mexico Market Segmentation Nigeria Africa 11% 12 % Brazil FY25 FY26 FY26 Top 10 Export Destinations Presence in 100+ Countries across 6 Continents ensures diversif [Showing first 8,000 characters — download PDF for full document]